Key facts
- Animab’s last known valuation is $16.0M (Nov 2022).
- It has raised $25.4M; the latest was Later Stage VC ($11.5M) in Jul 2025.
- Notable investors include Participatiemaatschappij Vlaanderen, VIB, Agri Investment Fund, Ghent University Endowment, Anacura — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Animab
- ·The full record, as it builds
Funding rounds
No funding rounds for Animab are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Animab
Developer of monoclonal antibodies designed to bring to the market cost-effective services that ultimately benefit animals, producers, and consumers. The company's antibodies utilize proprietary research discoveries to target speed and precision-specific intestinal pathogens in livestock without altering the healthy microbiome, enabling piglets to remain protected during their most fragile post-weaning stage.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Gent, Belgium
- Founded
- 2020
- Employees
- 10
- Website
- animab.com/
- Ownership
- Privately Held (backing)
Animab doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Animab shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Animab in its N-PORT filings yet. We sweep new filings monthly.